Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mutations

Mutations

Mutations

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The in ovo chorioallantoic membrane (CAM) is grafted with fresh sarcoma-derived tumor tissues, their single cell suspensions, and permanent and transient fluorescently labeled established sarcoma cell lines. The model is used to study graft- (viability, Ki67 proliferation index, necrosis, infiltration) and host (fibroblast infiltration, vascular ingrowth)...

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

We present here a cell culture method for inducing mesenchymal-epithelial transitions (MET) in sarcoma cells based on combined ectopic expression of microRNA-200 family members and grainyhead-like 2 (GRHL2). This method is suitable for better understanding the biological impact of phenotypic plasticity on cancer aggressiveness and...

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

The following protocol focuses on the establishment of a primary culture of patient-derived soft tissue sarcoma (STS). This model could help us to better understand the molecular background and pharmacological profile of these rare malignancies and could represent a starting point for further research aimed at improving STS...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Hematological oncology·2026

Same author

Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.

Blood cancer journal·2026

Same author

U2AF regulates the translation and localization of nuclear-encoded mitochondrial mRNAs.

Molecular cell·2026

Same author

A Case of Chronic Elephantiasis Nostra Verrucosa Highlighting the Progression of Chronic Lymphedema.

Cureus·2026

Same author

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Expert review of hematology·2026

Same author

Clinical utility of interim bone marrow biopsies in FLT3 mutant acute myeloid leukemia.

Leukemia research·2026

Same journal

CD19-negative relapse with an apparent cytogenetic shift after blinatumomab-induced measurable residual disease clearance in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Leukemia research reports·2026

Same journal

Synchronous presentation of pH+ B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia treated with blinatumomab.

Leukemia research reports·2026

Same journal

Expression of SLAMF7 on hairy cell leukemia indicates therapy option with SLAMF7-antibody Elotuzumab.

Leukemia research reports·2026

Same journal

Corrigendum to Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells [Leukemia Research Reports 25 (2026) 100570.1-1].

Leukemia research reports·2026

Same journal

Emphasizing the diagnostic and management challenge: Nodular sclerosis Hodgkin lymphoma with pericardial infiltration in an adolescent male - A case report.

Leukemia research reports·2026

Same journal

Treatment outcomes of acute leukemia during pregnancy at the National Institute of Hematology and Blood Transfusion.

Leukemia research reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 20, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

T315I-mutated myeloid sarcoma.

Yumeng Zhang¹, David M Swoboda², Aditya Grover¹

¹University of South Florida, Tampa, FL 33612, United States.

Leukemia Research Reports

|September 6, 2019

Summary

This summary is machine-generated.

Myeloid sarcoma is a rare complication of chronic myeloid leukemia. This case highlights successful treatment of T315I mutated myeloid sarcoma with chemotherapy and ponatinib.

Keywords:

Chronic myelogenous leukemia Myeloid sarcoma T315I mutation

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Jan 20, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Area of Science:

Hematology
Oncology
Molecular Biology

Background:

Myeloid Sarcoma (MS) is an extramedullary tumor of immature granulocytes, rarely associated with Chronic Myeloid Leukemia (CML).
CML is driven by the BCR-ABL1 fusion gene, targeted by tyrosine kinase inhibitors (TKIs).
TKI resistance, often due to the ABL1 T315I mutation, poses a therapeutic challenge.

Observation:

We present the first reported case of T315I mutated myeloid sarcoma in a patient with chronic phase CML.
This occurred despite achieving a complete cytogenetic response to dasatinib therapy.

Findings:

The patient with T315I mutated myeloid sarcoma and CML achieved remission.
Successful treatment involved induction chemotherapy followed by ponatinib.

Implications:

This case demonstrates a viable therapeutic strategy for T315I mutated myeloid sarcoma in CML.
It underscores the importance of monitoring for resistance mutations and considering alternative therapies like ponatinib.